Table 1.
Clinicopathologic features of HER2-positive pure mucinous carcinoma
| Case | Age (yr) | Sex | Procedure | Mass size (mm) | T category | No. of positive LNs | N category | Nuclear | Histologic grade | ER | PR | Type A/B | Structure | Recurrence | Follow-up | Trastuzumab | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 60 | F | T | A | 30.0 | 2 | 0 | 0 | 3 | III | - | - | B | SRC | NED | ND | |
| 2 | 41 | F | B | S | 15.0 | 1 | 0 | 0 | 3 | III | + | + | B | None | NED | ND | |
| 3 | 43 | F | T | S | 3.0 | 1 | 0 | 0 | 2 | II | + | + | A | None | NED | ND | |
| 4 | 28 | F | B | S | 15.0 | 1 | 0 | 0 | 3 | III | + | + | B | SRC | NED | ND | |
| 5 | 60 | F | T | A | 70.0 | 3 | 1 | 1 | 3 | III | - | - | A | MP/SRC | NED | ND | |
| 6 | 43 | F | B | S | 4.0 | 1 | 0 | 0 | 2 | II | - | + | A | None | NED | ND | |
| 7 | 53 | F | T | S | 4.5 | 1 | 0 | 0 | 2 | II | + | - | B | SRC | NED | ND | |
| 8 | 46 | F | T | A | 65/60a | 3 | 5 | 2 | 2 | II | - | - | A | MP/SRC | Local recurrence | DOD | ND |
| 9 | 39 | F | T | A | 38.0 | 2 | 0 | 0 | 2 | II | + | + | NA | None | Metastasis to lung and brain | DOC | ND |
| 10 | 55 | F | B | S | 15.0 | 1 | 0 | 0 | 3 | III | + | + | A | MP | NED | NA | |
| 11 | 37 | F | B | S | 55/0a | 3 | NAb | NAb | 2 | II | - | + | B | SRC | NED | Donec | |
| 12 | 46 | F | T | A | 85/70a | 3 | 7 | 2 | 3 | III | + | + | A | None | NED | Donec | |
| 13 | 48 | F | B | A | 90/80a | 3 | 1 | 1 | 2 | II | + | + | A | SRC | NED | Donec | |
| 14 | 63 | F | B | S | 16.0 | 1 | 0 | 0 | 3 | III | + | + | A | SRC | NED | Done | |
| 15 | 40 | F | B | A | 30/10a | 2 | 2 | 1 | NA | NA | + | + | NA | NA | NED | Done | |
| 16 | 38 | F | B | S | 12.0 | 1 | 0 | 0 | 2 | II | - | - | A | MP | NED | Done | |
| 17 | 32 | F | T | A | 16.0 | 1 | 0 | 0 | 3 | III | + | + | A | SRC | NED | Done | |
| 18 | 34 | F | B | S | 40.0 | 2 | 0 | 0 | 2 | II | - | - | A | SRC | NED | Done | |
| 19 | 41 | F | T | A | 41.0 | 2 | 2 | 1 | 3 | III | + | + | B | SRC | NED | Done | |
| 20 | 50 | F | B | S | 16.0 | 1 | 0 | 0 | 2 | II | + | + | A | SRC | NED | Done | |
| 21 | 54 | F | T | A | 16/19a | 1 | 22 | 3 | 3 | III | + | + | A | MP | Metastasis to skin and lung | DOC | Done |
HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor; F, female; T, total mastectomy; A, axillary lymph node dissection; SRC, signet ring cells; NED, no evidence of disease; ND, not done; B, breast conserving surgery; S, sentinel lymph node biopsy; MP, micropapillary; DOD, died of disease; NA, not applicable; DOC, died of other cause.
a
For cases with neoadjuvant chemotherapy, tumor size before/after treatment were recorded;
b
In this patient, lymph node metastasis was suspected in radiologic images, but pathologic confirmation was not performed due to pathologic complete response;
c
Used trastuzumab for neoadjuvant chemotherapy.